Novartis Investigative Site

Kunming, Yunnan 650106

0 studies enrolling now · 5 studies all time

What they study most

Advanced Solid Tumors Which Are cMET-dependent, Autoimmunity, Inflammation, Cardiovascular Disease, Metastatic Breast Cancer, Primary Immune Thrombocytopenia (ITP), Type 2 Diabetes Mellitus

Studies at this site

• Secukinumab Open Label Roll-over Extension Protocol — Recruiting now
• Roll-over Study to Allow Continued Access to Ribociclib — Running, not enrolling
• Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) — Running, not enrolling
• Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone — Running, not enrolling
• Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases) — Stopped early